Adaptimmune Therapeutics (NASDAQ:ADAP) Shares Down 6.6%

Share on StockTwits

Adaptimmune Therapeutics PLC – (NASDAQ:ADAP)’s share price traded down 6.6% during trading on Thursday . The company traded as low as $1.08 and last traded at $1.14, 518,218 shares traded hands during trading. An increase of 66% from the average session volume of 311,967 shares. The stock had previously closed at $1.22.

Several research analysts recently weighed in on the stock. ValuEngine raised shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. Cowen reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Thursday, November 7th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics has an average rating of “Hold” and a consensus price target of $6.59.

The business has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $2.20. The company has a current ratio of 3.93, a quick ratio of 3.93 and a debt-to-equity ratio of 0.15. The company has a market cap of $119.35 million, a PE ratio of -1.19 and a beta of 1.82.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.36) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.03). The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $7.00 million. On average, equities research analysts expect that Adaptimmune Therapeutics PLC – will post -1.37 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of ADAP. Baillie Gifford & Co. grew its holdings in Adaptimmune Therapeutics by 7.9% in the second quarter. Baillie Gifford & Co. now owns 4,143,840 shares of the biotechnology company’s stock valued at $16,658,000 after purchasing an additional 304,650 shares during the period. Aperio Group LLC acquired a new position in Adaptimmune Therapeutics in the second quarter valued at $88,000. Man Group plc boosted its holdings in Adaptimmune Therapeutics by 37.4% in the second quarter. Man Group plc now owns 1,839,225 shares of the biotechnology company’s stock valued at $7,394,000 after acquiring an additional 500,595 shares during the last quarter. Acadian Asset Management LLC grew its position in Adaptimmune Therapeutics by 119.5% during the second quarter. Acadian Asset Management LLC now owns 42,517 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 23,143 shares during the period. Finally, Rock Springs Capital Management LP grew its position in Adaptimmune Therapeutics by 9.4% during the second quarter. Rock Springs Capital Management LP now owns 875,000 shares of the biotechnology company’s stock valued at $3,518,000 after acquiring an additional 75,000 shares during the period. Institutional investors own 65.06% of the company’s stock.

Adaptimmune Therapeutics Company Profile (NASDAQ:ADAP)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Featured Article: Earnings Per Share

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.